STRATA Skin Sciences to Participate in June Dermatology Conferences

HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its participation in two dermatology conferences in the month of June.

On June 1, STRATA has participated in the inaugural Schweiger Symposium at the Jacob Javits Center in New York City. The Symposium brought together dermatology providers and leaders from multiple states for a day of presentations and professional development sessions and was headed by Dr. Eric Schweiger and the Schweiger Dermatology Group leadership team. STRATA presented, had a marketing booth highlighting its XTRAC^® and TheraClear^®X devices, and was available for discussions about the applications and advantages of each. As of the end of the first quarter of 2024 STRATA had XTRAC^® and/or TheraClear^®X devices in over 35 individual offices that are part of the 110 Schweiger Dermatology Group existing offices. For more information about the Schweiger Symposium, please visit this .

On June 21, STRATA will participate in the Global Vitiligo Foundation Physician Education Summit at the Marriott Indianapolis North in Indianapolis. The Summit is a medical educational meeting designed to equip dermatologists with knowledge and tools needed for accurate vitiligo identification, diagnosis, and treatment. Leading vitiligo specialists will share latest findings and facilitate discussions. STRATA will be participating in a demonstration at the Summit, as well as highlighting the benefits of vitiligo treatment using its XTRAC^® device. For more information about the Global Vitiligo Foundation Physician Education Summit, please visit this .

“Participating in these two conferences highlights the key growth drivers for STRATA’s unique recurring revenue business,” said Dr. Dolev Rafaeli, STRATA president and CEO, “With penetration of 30% or more into the private equity backed dermatology office groups, we intend to keep promoting best practices across these groups and expanding the use of the XTRAC^® device for treatment beyond psoriasis and into vitiligo and eczema.”

About STRATA Skin Sciences

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^® excimer laser, VTRAC^® lamp systems, and the TheraClear^®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure (versus an equipment purchase), installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at  and .

Investor Contact:

CORE IR

516-222-2560